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The t(6;14) translocation juxtaposing the 
immunoglobulin heavy chain gene to the IRF4 gene 
have been shown to activate the transcription factor 
MUM1/IRF4 in multiple myeloma and in a subtype of 
mature B-cell lymphomas (Iida et al., 1997; Salaverria 
et al., 2011).  
The translocation leads to the overexpression of the 
MUM1/IRF4 gene. 
In multiple myeloma, IRF4 is similarly juxtaposed by
an illegitimate IG switch recombination to the IG loci 
(Iida et al., 1997).  
Moreover, in multiple myeloma, expression of IRF4 is 
not only driving those cases with IG/IRF4-fusion but is 
also essential for survival in cases lacking this 
translocation (Shaffer et al., 2008). 
Specifically IGH/IRF4 and its variants fusions are 
associated with a subgroup of GC B-cell lymphomas 
composing follicular lymphoma grade 3 or 
centroblastic DLBCL characterized by coexpression of 
MUM1 and BCL6 in the absence of PRDM1/BLIMP1, 
a specific gene expression profile, and a disease on t 
predominantly in childhood or young adulthood 
(Salaverria et al., 2011). 
Clinics and pathology 
Disease 
Multiple myeloma (MM) 
Phenotype/cell stem origin 
Plasma Cell. MUM1+/BCL6-/BLIMP1+. 
Epidemiology 
Rare translocation, <1% (Tamura et al., 2000). Not one
of the five recurrent IGH translocations in MM 




As a result, the MUM1/IRF4 gene is overexpressed, an 
event that contributes to tumorigenesis.  
The clinical significance of this alteration in MM 
remains unknown. 
Disease 
B-cell lymphoma, follicular lymphoma, diffuse large 
B-cell lymphoma 
Phenotype/cell stem origin 
Germinal Center derived. MUM1+/BCL6+/BLIMP1-. 
Epidemiology 
Rare translocation. Present in 15% and 2% of the 
pediatric and adult GCB derived B-cell lymphomas 
respectively (Salaverria et al., 2011). 
Clinics 
Clinical presentation is significantly skewed toward the 
involvement of the head and neck region, including 
Waldeyer ring and limited disease stages (Salaverria t 
al., 2011). 
Prognosis 
IG/IRF4-positive cases are associated with a 
significantly better prognosis, although this effect is  
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Fluorescence in situ hybridization (FISH) analyses for the detection of IRF4 breaks in, the signal constellation shows IRF4 breaks and 
IGH-IRF4 fusion in two cases of B-cell lymphoma respectively. 
 
predominantly associated with the low age of the 




In MM, three cell lines have showed fusions between 
these two loci, which resulted in the juxtaposition f 
the MUM1 to the IgH 3' alpha-enhancer region by 
virtue of t(6;14) or insertion of the IgH sequences into 
the vicinity of the MUM1 gene and in the concomitant 
overexpression of the MUM1 mRNA (Yoshida et al., 
1999). 
In germinal center derived lymphomas, long-distance 
inverse PCR for cloning the IGH partner have been 
used. Sµ-long-distance inverse PCR has detected a 
switch µ-associated translocation t(6;14)(p25;q32) in 
two cases. Both translocations disrupted the coding 
region of EXOC2. Immediately telomeric of EXOC2 
maps the IRF4 gene, which through the translocation is 
juxtaposed to the IGH locus on the der(14)t(6;14) in the 
same transcriptional direction (Salaverria et al., 2011). 
The breakpoints might be located on either side of 
IRF4 and can affect the DUSP22 gene, immediately 
telomeric and the EXOC2 gene centromeric to IRF4.  
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In this sense, a recent sequencing study has describ d 
in a young DLBCL patient carrying a fusion between 
6p25 and 14q32, juxtaposing IGH with the DUSP22 
gene (Morin et al., 2011). 
Cytogenetics 
Cytogenetics morphological 
t(6;14)(p25;q32) is cytogenetically cryptic, not 
detectable by means of conventional cytogenetic 
analysis (Yoshida et al., 1999). 
Cytogenetics molecular 
FISH constellation have demonstrated juxtaposition of 
IGH and IRF4. 
Additional anomalies 
In germinal center derived lymphomas, the IG/IRF4-
positive lymphomas had fewer chromosomal 
imbalances suggesting that the IRF4 translocation is an 
early event in lymphomagenesis. In MM, the secondary 
copy number changes of the positive cases are 
unknown. 
Variants 
Light chain variants t(2;6)(p12;p25), t(6;22)(p25;q11). 
IRF4 breakpoints with unknown translocation partner. 
Genes involved and proteins 






Lymphocyte specific; The transcription factor 
MUM1/IRF4 is required during an immune response 
for lymphocyte activation and the generation of 
immunoglobulin-secreting plasma cell. 




IgH is composed of IGHV genes, IGHD segments, 
IGHJ segments, and IGHC genes. 
Protein 
IgH encodes the immunoglobulin heavy chains. 




IRF4 translocated on chromosome 14. 
Fusion protein 
Description 
No fusion protein; the immunoglobulin gene enhancer 
stimulates the expression of IRF4. 
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